Scarring Alopecias: Pathology and an Update on Digital Developments

    November 2021 in “ Biomedicines
    Donna M. Cummins, Iskander H. Chaudhry, Matthew Harries
    Image of study
    TLDR New digital tools are improving the diagnosis and understanding of irreversible hair loss conditions.
    The document "Scarring Alopecias: Pathology and an Update on Digital Developments" discusses the challenges in diagnosing primary cicatricial alopecias (PCA), irreversible hair loss conditions due to the destruction and fibrosis of hair follicles. It emphasizes the importance of communication between the clinician, laboratory, and histopathologist, and the use of special stains in diagnosis. The document also discusses the North American Hair Research Society's classification of PCA, the speculated pathogenesis of cicatricial alopecia, and the histopathology of PCAs. It provides details on various types of scarring alopecias, including Discoid lupus erythematosus (DLE), Central Centrifugal Cicatricial Alopecia (CCCA), Pseudopelade of Brocq (PsB), and Folliculitis decalvans. The document also highlights the potential of digital pathology, specifically Whole Slide Imaging (WSI), in improving specialist hair loss services and the potential of artificial intelligence in advancing digital technologies in the field of hair loss.
    Discuss this study in the Community →

    Research cited in this study

    21 / 21 results

    Related Community Posts Join

    6 / 282 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 3 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  121 upvotes 5 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Related Research

    7 / 7 results